PharmacyCodes



Repaglinida [Inn-Spanish] en es it fr

Categoria

Repaglinida [Inn-Spanish] Nombres de marca, Repaglinida [Inn-Spanish] Analogos

Repaglinida [Inn-Spanish] Marca los nombres de mezcla

  • No information avaliable

    • Repaglinida [Inn-Spanish] Formula quimica

    C27H36N2O4

    Repaglinida [Inn-Spanish] RX enlace

    http://www.rxlist.com/cgi/generic/prandin.htm

    Repaglinida [Inn-Spanish] FDA hoja

    Repaglinida_[Inn-Spanish] FDA

    Repaglinida [Inn-Spanish] MSDS (hoja de seguridad de materiales)

    Repaglinida_[Inn-Spanish] MSDS

    Repaglinida [Inn-Spanish] Sintesis de referencia

    W. Grell et al., Int. PCT. pat. Appl. WO 93 00337

    Repaglinida [Inn-Spanish] Peso molecular

    452.586 g/mol

    Repaglinida [Inn-Spanish] Punto de fusion

    130-131 oC

    Repaglinida [Inn-Spanish] H2O Solubilidad

    No hay información disponible

    Repaglinida [Inn-Spanish] Estado

    Solid

    Repaglinida [Inn-Spanish] LogP

    5.798

    Repaglinida [Inn-Spanish] Formas de dosificacion

    Tableta

    Repaglinida [Inn-Spanish] Indicacion

    Para el tratamiento de la diabetes mellitus tipo II.

    Repaglinida [Inn-Spanish] Farmacologia

    Repaglinida es un sangre por vía oral para disminuir la glucosa de drogas de la clase meglitinida utilizados en el tratamiento de diabetes mellitus tipo 2 (también conocida como diabetes no insulino dependiente mellitus o NIDDM). Repaglinida disminuye los niveles de glucosa en la sangre, estimulando la secreción de insulina del páncreas. Esta acción depende de funcionamiento de las células beta de los islotes pancreáticos. La liberación de insulina es dependiente de la glucosa y disminuye en las concentraciones de glucosa baja.

    Repaglinida [Inn-Spanish] Absorcion

    Rápido (la biodisponibilidad es del 56%)

    Repaglinida [Inn-Spanish] Toxicidad

    LD50> 1 g / kg (rata) (W. Grell)

    Repaglinida [Inn-Spanish] Informacion de Pacientes

    PATIENT INFORMATION

    Patients should be informed of the potential risks and advantages of Repaglinide (PRANDIN) and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA1c. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.

    Patients should be instructed to take Repaglinide before meals (2, 3, or 4 times a day preprandially). Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.

    Repaglinida [Inn-Spanish] Organismos afectados

    Humanos y otros mamíferos